TriangleNCT01812252 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Up to 18 months
What was measured
The total length of follow-up will be 18 months from the start of treatment (day 1). Four categories were added for participants alive 18 months from start of treatment (day 1) 1) Participants alive after 18 months from start of treatment who received hematopoietic cell transplantation (HCT); 2) Participants alive after 18months from start of treatment who did not receive HCT.; 3) Participants deceased after 18 months from start of treatment who received HCT; 4) Participants deceased after 18 months from start of treatment who did not receive HCT.
Groups in this outcome
Arm A (Decitabine or Azacitidine)
Patients receive decitabine or azacitidine IV or SC per standard of care. Treatment repeats per standard of care, every 28 days for 4 cycles of decitabine or 6 cycles of azacitidine in the absence of disease progression or unacceptable toxicity. Azacitidine (AZC): Given IV or SC Decitabine: Given IV or SC Quality-of-Life Assessment: Ancillary studies
Arm B (Induction-like Chemotherapy Regimen)
Patients receive physician choice of standard of care or other experimental protocol using induction-like chemotherapy regimen. No one specific regimen is required. Several regimens are listed in the protocol for example only. Quality-of-Life Assessment: Ancillary studies
| Group | Source count |
|---|---|
| Arm A (Decitabine or Azacitidine) | 25 |
| Arm B (Induction-like Chemotherapy Regimen) | 25 |
Reported measurements
Source class 1
Participants alive after 18 months from start of treatment who received HCT.
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm A (Decitabine or Azacitidine) | 7 | Not reported | Not reported | Not reported | Not reported |
| Arm B (Induction-like Chemotherapy Regimen) | 10 | Not reported | Not reported | Not reported | Not reported |
Participants alive after 18months from start of treatment who did not receive HCT.
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm A (Decitabine or Azacitidine) | 2 | Not reported | Not reported | Not reported | Not reported |
| Arm B (Induction-like Chemotherapy Regimen) | 1 | Not reported | Not reported | Not reported | Not reported |
Participants deceased after 18 months from start of treatment who received HCT.
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm A (Decitabine or Azacitidine) | 5 | Not reported | Not reported | Not reported | Not reported |
| Arm B (Induction-like Chemotherapy Regimen) | 3 | Not reported | Not reported | Not reported | Not reported |
Participants deceased after 18 months from start of treatment who did not receive HCT.
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm A (Decitabine or Azacitidine) | 11 | Not reported | Not reported | Not reported | Not reported |
| Arm B (Induction-like Chemotherapy Regimen) | 11 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 7
- group Id
- OG001
- value
- 10
- title
- Participants alive after 18 months from start of treatment who received HCT.
- measurements
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 1
- title
- Participants alive after 18months from start of treatment who did not receive HCT.
- measurements
- group Id
- OG000
- value
- 5
- group Id
- OG001
- value
- 3
- title
- Participants deceased after 18 months from start of treatment who received HCT.
- measurements
- group Id
- OG000
- value
- 11
- group Id
- OG001
- value
- 11
- title
- Participants deceased after 18 months from start of treatment who did not receive HCT.
- denoms
- counts
- group Id
- OG000
- value
- 25
- group Id
- OG001
- value
- 25
- units
- Participants
- description
- The total length of follow-up will be 18 months from the start of treatment (day 1). Four categories were added for participants alive 18 months from start of treatment (day 1) 1) Participants alive after 18 months from start of treatment who received hematopoietic cell transplantation (HCT); 2) Participants alive after 18months from start of treatment who did not receive HCT.; 3) Participants deceased after 18 months from start of treatment who received HCT; 4) Participants deceased after 18 months from start of treatment who did not receive HCT.
- groups
- description
- Patients receive decitabine or azacitidine IV or SC per standard of care. Treatment repeats per standard of care, every 28 days for 4 cycles of decitabine or 6 cycles of azacitidine in the absence of disease progression or unacceptable toxicity. Azacitidine (AZC): Given IV or SC Decitabine: Given IV or SC Quality-of-Life Assessment: Ancillary studies
- id
- OG000
- title
- Arm A (Decitabine or Azacitidine)
- description
- Patients receive physician choice of standard of care or other experimental protocol using induction-like chemotherapy regimen. No one specific regimen is required. Several regimens are listed in the protocol for example only. Quality-of-Life Assessment: Ancillary studies
- id
- OG001
- title
- Arm B (Induction-like Chemotherapy Regimen)
- param Type
- COUNT_OF_PARTICIPANTS
- reporting Status
- POSTED
- time Frame
- Up to 18 months
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice